About

MPN Cancer Connection Mission (MPN-CC)

To continue helping MPN patients by expanding the wide range of resources available through PV Reporter & MPN-CC, empowering patients to better understand treatment options and improve patient care by recognizing MPNs are a cancer, offering access to a broad range of benefits and program assistance.

About

MPN Cancer Connection (MPN-CC) was created by David Wallace. He is also the publisher and founder of PV Reporter, a website created to provide “easy access” to a wealth of MPN information. PV Reporter becomes the sister website to MPN Cancer Connection.

Funds raised will be used to cover on going expenses in publishing PV Reporter (launched during the summer of 2013) and MPN-CC, reporting and traveling to MPN events, raising MPN Awareness and growing resources for MPN patients and caregivers.

How it started

David Wallace was 47 when he was diagnosed with polycythemia vera (PV) in 2009. A self-proclaimed “aspiring web designer, publisher, writer, patient advocate and chief bottle washer,” David used his diagnosis as a motivating factor to push himself to always learn something new. Utilizing social media to connect with informed patients and to gain a better understanding of emerging treatments, he found himself in an intense period of adjusting to a new norm of having a rare blood cancer for which doctors didn’t have a standard protocol for treatment. David developed PVReporter.com, a comprehensive, easy-to-navigate, patient-focused website for myeloproliferative neoplasms (MPNs). David’s philosophy is straightforward: “Educating the patient is essential, so the patient can guide their physician to meet his or her needs.” MPN Cancer Connection is a “patient focused” project to help educate and empower MPN patients by providing the necessary resources and funding for PV Reporter.
300k

U.S. Patients


Are living with an MPN
148k

People


Are living with Polycythemia Vera (PV)
135k

People


Are living with Essential Thrombocythemia (ET)
18k

People


are living with Myelofibrosis (MF)